The study of ways to minimize the cost of treating seasonal allergy in Ukraine
DOI:
https://doi.org/10.24959/nphj.20.34Keywords:
seasonal allergy, blockers of H1-histamine receptors of the II generation, ATC/DDD-methodology, cost minimization analysisAbstract
Seasonal allergy is a common pathology throughout the world and is the leading one in the structure of human diseases in terms of socioeconomic losses. The Pharmacist’s protocol for dispensing over-the-counter (OTC) drugs in Ukraine recommends the use of the II generation histamine H1 receptor blockers for the treatment of this pathology.
Aim. To rationalize the choice of blockers of H1-histamine receptors of the second generation for the treatment of seasonal allergies based on the cost minimization analysis.
Materials and methods. The research materials were the Pharmacist’s protocol for dispensing over-the-counter medicines; data of the State Register of Medicines of Ukraine as of January 2020; the Register of wholesale prices for medicines as of January 15, 2020; wholesale prices for medicines of the national distributor of the pharmaceutical market BaDM LLC dated 03.20.2020 according to the weekly “Apteka”. The following research methods were used: descriptive analysis, frequency analysis, marketing analysis, pharmaco-epidemiological analysis – ATC/DDD-methodology, cost minimization analysis, NNT-coefficient calculation.
Results and discussion. It was found that at the pharmaceutical market of Ukraine at the beginning of 2020, 10 drugs of blockers of the second generation H1-histamine receptors according to INN and 92 by the trade names (TN) were presented; of them foreign drugs were 76.36 %, domestic ones – 23.64 %. According to the ATC/DDD methodology, significant fluctuations from 0.72 UAH up to 49.57 UAH were revealed in the cost of DDDs among the generics of the drugs studied. The cost minimization analysis for the drugs studied showed that the NNT coefficient for desloratadine was 3.99; levocetirizine – 3.58; loratadine – 2.69; fexofenadine – 1.10; fenspiride – 1.53; chifenadine – 2.59; cetirizine – 1.49.
Conclusions. The study conducted has shown that the savings for the treatment of seasonal allergies can range from 3100 UAH up to 304200 UAH when choosing the cheapest generic blockers of H1-histamine receptors of the II generation.
References
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy.
Alerhichnyi rynit. Available at: http://www.lorlife.kiev.ua/rhinology/2017/2017_3_4_19.pdf.
Vsesvitnia orhanizatsiia okhorony zdorov’ia. Available at: https://www.who.int/countries/ukr/ru/.
Iakovlieva, L. V., Berdnyk, O. H., Hurtiakova, A. O. (2018). Analiz asortymentu, dostupnosti y obsiahiv spozhyvannia antyhistaminnykh
likarskykh zasobiv v Ukraini. Farmatsevtychnyi zhurnal, 1-2, 12–18.
Nakaz MOZ Ukrainy vid 11 zhovtnia 2013 roku №875 «Protokol provizora (farmatsevta) pry vidpusku bezretsepturnykh likarskykh zasobiv. Symptomatychne likuvannia alerhii». dec.gov.ua. Available at: https://dec.gov.ua/mtd/protokoly-provizora-farmaczevta/.
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/.
Reiestr optovo-vidpusknykh tsin na likarski zasoby stanom na 15.01.2020 roku. Available at: https://moz.gov.ua/reestr-optovo-vidpusknih-cin-na-likarski-zasobi.
Dani optovykh tsin na likarski zasoby natsionalnoho dystrybiutora farmatsevtychnoho rynku TOV «BaDM» vid 20.03.2020 r. Available at: https://pharmbase.com.ua/ru/.
ATC/DDD Index 2020. Available at: https://www.whocc.no/atc_ddd_index/.
Germanyuk, T. A., Ivko, T. I. (2014). Metodolohiia marketynhovykh, farmakoepidemiolohichnykh ta farmako-ekonomichnykh doslidzhen. Vinnytsia: Tvory, 14–23; 31–33.
Iakovlieva, L. V. (2009). Farmakoekonomika. Kharkiv, 101–144.
Germanyuk, T. A., Bobruk, V. P., Balanchuk, T. I., Tykholaz, S. I. (2018). Suchasni klasyfikatsii osnovnykh likarskykh zasobiv. Vinnytsia: Tvory, 19–20.
Kompendium-2020. URL: https://compendium.com.ua/.
Spravochnik lekarstvennykh sredstv VIDAL. URL: https://www.vidal.ru/.
Germanyuk, T. A., Ivko, T. I. (2015). Optymizatsiia likarskoho zabezpechennia khvorykh na tsukrovyi diabet 2 typu na osnovi farmakoekonomichnykh doslidzhen. Kyiv: Ukrainskyi tsentr naukovoi medychnoi informatsii ta patentno-litsenziinoi roboty, 9.
Ivko, T., Germanyuk, T., Bobritskaya, L. (2017). The study of the Ukrainian pharmaceutical market of laxatives. News of pharmacy, 1 (89), 43–44. doi: https://doi.org/10.24959/nphj.17.2145.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
